- Sézary lymphoma
- Sézary syndrome
- Sezary's lymphoma
- Topical corticosteroids.
- Topical chemotherapy with mechlorethamine (nitrogen mustard) or carmustine (BCNU).
- Psoralen and ultraviolet A radiation (PUVA).
- Ultraviolet B radiation (UVB).
- Total-skin electron-beam radiation (TSEB).
- Radiation of symptomatic skin lesions.
- Interferon-alpha alone or in combination with topical therapy.
- Single-agent and multiagent chemotherapy.
- Bexarotene (topical gel or oral); retinoids.
- Denileukin diftitox (recombinant fusion protein of diptheria toxin fragments and interleukin-2 sequences).
- Combined modality treatment.
These types of treatments are aimed at producing remissions and improving symptoms. Treatment, therefore, is considered palliative for most patients. Survival in excess of 8 years is common. Patients with Sezary syndrome may benefit from participation in clinical trials evaluating new approaches to treatment.
More details about treatment of Sezary syndrome can be accessed by clicking here.
- Mycosis Fungoides and Sezary Syndrome Treatment (PDQ) - Treatment Option Overview. National Cancer Institute (NCI). 2010; http://www.cancer.gov/cancertopics/pdq/treatment/mycosisfungoides/HealthProfessional/page4. Accessed 2/8/2011.
- ClinicalTrials.gov lists trials that are studying or have studied Sezary syndrome. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies.
- Orphanet is a European reference portal for information on rare diseases and orphan drugs. Access to this database is free of charge.
- The Research Portfolio Online Reporting Tool (RePORT) provides access to reports, data, and analyses of research activities at the National Institutes of Health (NIH), including information on NIH expenditures and the results of NIH-supported research. Although these projects may not conduct studies on humans, you may want to contact the investigators to learn more. To search for studies, enter the disease name in the "Text Search" box. Then click "Submit Query".